American Herbal Products Association (AHPA) > Resources > Regulations > Government Advocacy

Recent AHPA Advocacy

AHPA recommends CBD not be scheduled under any international drug control convention

AHPA submits comments to FDA to inform participation in WHO Expert Committee on Drug Dependence

AHPA submitted comments to the Food and Drug Administration (FDA) yesterday to stress that cannabidiol (CBD) requires no international drug scheduling as an individual substance and encourage the U.S. to support this position.
Rate of NDI notifications reported by FDA unexpectedly drops

Rate of NDI notifications reported by FDA unexpectedly drops

More than half of most recent NDI notifications available from FDA filed without comment

More than half of the most recent new dietary ingredient (NDI) notifications provided by the Food and Drug Administration (FDA) in the last six months were filed without comment, but the rate of notifications reported received by the agency is dramatically lower than previously observed for any six month period since the initial six months in 1995 when the agency first began accepting and filing notifications.

AHPA supports FDA Guidance making pure or highly concentrated caffeine dietary supplements unlawful

AHPA policy prohibits the sale of pure caffeine

FDA issued guidance titled, "Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry," to explain that it generally considers pure or highly concentrated caffeine dietary supplements, sold in bulk directly to consumers, to be adulterated because they present a significant or unreasonable risk of illness or injury. The principle in this guidance is consistent with a policy adopted by AHPA members in 2015.
AHPA staff participate in panels on pesticides and food adulteration prevention at GMA Science Forum

AHPA staff participate in panels on pesticides and food adulteration prevention at GMA Science Forum

AHPA President Michael McGuffin presented on a panel discussing pesticide issues

AHPA President Michael McGuffin and Chief Science Officer Holly Johnson, Ph.D. presented at the Grocery Manufacturers Association (GMA) Science Forum held this week in Washington, DC.
AHPA comments to FWS provide recommendations for CITES

AHPA comments to FWS provide recommendations for CITES

Annotation for American ginseng should exclude sliced roots from CITES export and import controls

In comments submitted to U.S. Fish and Wildlife Service (FWS), AHPA requested that the agency propose at the 18th Conference of the Parties (CoP18) of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) to amend the annotation for American ginseng (Panax quinquefolius) to exclude sliced roots from CITES export and import controls.

IADSA update on international supplement regulations

IADSA February 2018 Newsflash

This issue of the IADSA Newsflash includes an update on France's new maximum levels for vitamins and minerals in supplements

AHPA recommends regulatory improvements in comments submitted to CFSAN

Recommendations seek to reduce regulatory burdens while maintaining consumer protections

The American Herbal Products Association (AHPA) submitted nearly 100 pages of comments today to the Food and Drug Administration (FDA) Center for Food Safety and Applied Nutrition (CFSAN) identifying numerous ways to improve regulations, guidance documents, and enforcement practices to protect public health more effectively and efficiently.
McGuffin statement on Sen. Hatch retirement

McGuffin statement on Sen. Hatch retirement

DSHEA was a remarkable achievement, made possible in large part by Sen. Hatch’s persistence and hard work

American Herbal Products Association (AHPA) President Michael McGuffin issued the following statement regarding the retirement of Sen. Orrin Hatch (R-UT), a vocal dietary supplement advocate who helped shape the laws that regulate the industry.
Industry Coalition Reminds Consumers, Retailers, and Product Marketers that Dietary Supplements Cannot Claim to Treat Opioid Addiction

Industry Coalition Reminds Consumers, Retailers, and Product Marketers that Dietary Supplements Cannot Claim to Treat Opioid Addiction

Industry trade associations have been consistent in taking strong positions against marketing dietary supplements for treatment or prevention of diseases

The dietary supplement industry is aware of growing concerns regarding significant negative health impacts associated with opioid addiction and abuse. The leading trade associations of the dietary supplement industry support the responsible marketing and use of health-promoting vitamins, minerals, herbs, sports nutrition, and other dietary supplements.

AHPA submits comments on pre-DSHEA dietary ingredient list

AHPA recommended that FDA make significant changes to previous positions on new dietary ingredients (NDIs)

AHPA's comments were submitted in response to FDA's request for input on issues related to the future development of a list of dietary ingredients marketed in the United States prior to October 15, 1994, when the Dietary Supplement Health and Education Act (DSHEA) became law.
RSS
12345678910 Last

2018 Annual Fund Sponsors

   

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.